Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, enhancing its ability to inactivate thrombin, factor Xa, and other serine proteases involved in blood coagulation.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes,Anticoagulation in extracorporeal circuits
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
5000 units IV bolus followed by continuous IV infusion of 1300 units/hour, adjusted to maintain a PTT of 1.5-2.5 times control.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Intravenous: 0.5–2.5 hours (dose-dependent); at therapeutic doses ~1.5 hours. Prolonged in hepatic or renal impairment.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Heparin is primarily metabolized in the liver and reticuloendothelial system, with some renal clearance. It is not metabolized by cytochrome P450 enzymes.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: negligible; primarily cleared by hepatic reticuloendothelial system and vascular endothelium via desulfation and depolymerization. No significant biliary or fecal elimination.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Extensive (~95%) to antithrombin III, fibrinogen, lipoproteins, and other plasma proteins.
Low protein binding; 0–11% bound, primarily to albumin.
0.06–0.1 L/kg (low, consistent with plasma volume). Does not cross placenta or blood-brain barrier.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Subcutaneous: 20–30% (due to high protein binding and degradation). Not administered orally.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No dose adjustment recommended for GFR >30 m L/min. For GFR 15-30 m L/min: reduce infusion rate by 20%. For GFR <15 m L/min: reduce infusion rate by 50%.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific Child-Pugh based guidelines. Use with caution in severe hepatic impairment; consider reduced doses due to decreased antithrombin III synthesis and potential for increased bleeding risk.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Initial IV bolus of 75-100 units/kg, followed by continuous infusion of 15-25 units/kg/hour, adjusted to achieve a PTT of 60-85 seconds.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Reduce initial bolus to 50 units/kg and continuous infusion to 10-20 units/kg/hour. Monitor a PTT closely; lower doses often required due to decreased drug clearance and increased bleeding risk.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Heparin can cause heparin-induced thrombocytopenia (HIT) with or without thrombosis. Monitor platelets closely.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of heparin-induced thrombocytopenia (HIT),Risk of bleeding, especially in patients with renal impairment or on antiplatelet therapy,Monitor coagulation parameters (a PTT),Use with caution in patients with history of HIT, recent surgery, or active bleeding
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITTS),Active major bleeding or bleeding disorders,Severe thrombocytopenia,Hypersensitivity to heparin or any component
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No significant food interactions. However, avoid excessive consumption of foods high in vitamin K (e.g., leafy greens) if on concurrent warfarin therapy, as heparin alone does not interact with vitamin K.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Heparin is a large molecule that does not cross the placenta; thus, it is not associated with teratogenicity or fetal bleeding. No increased risk of congenital anomalies has been reported in any trimester.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Heparin is not excreted into breast milk due to its high molecular weight and acidic nature. It is considered compatible with breastfeeding. M/P ratio is not available because milk concentrations are undetectable.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy is associated with increased plasma volume, renal clearance, and heparin-binding proteins, often requiring higher doses to maintain therapeutic a PTT. Dose should be adjusted based on a PTT monitoring, typically with increased requirements in the second and third trimesters.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Heparin 5,000 units in 0.9% Na Cl is typically used for venous thromboembolism prophylaxis. Monitor a PTT if using therapeutic dosing; for prophylactic doses, a PTT monitoring is usually not required. Use with caution in patients with renal impairment or history of HIT. Administer via IV infusion; do not mix with other drugs. Check platelet counts regularly to monitor for heparin-induced thrombocytopenia (HIT).
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is used to prevent blood clots. You will receive it as an infusion into your vein.,Report any signs of unusual bleeding or bruising, such as blood in urine/stool, coughing up blood, or nosebleeds.,Inform all healthcare providers that you are on heparin, especially before any surgery or dental procedures.,Do not take aspirin, ibuprofen, or other NSAIDs without consulting your doctor, as they may increase bleeding risk.,If you develop a rash, fever, or chills, notify your healthcare provider immediately.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, enhancing its ability to inactivate thrombin, factor Xa, and other serine proteases involved in blood coagulation.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 5000 units IV bolus followed by continuous IV infusion of 1300 units/hour, adjusted to maintain a PTT of 1.5-2.5 times control.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin is a large molecule that does not cross the placenta; thus, it is not associated with teratogenicity or fetal bleeding. No increased risk of congenital anomalies has been r. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.